Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ziresovir in Adults With Respiratory Syncytial Virus Infection
NCT03699202Phase 2Terminated
- Sponsor
- Ark Biosciences
- Start
- Mar 2019
- Primary completion
- Apr 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ziresovir in respiratory syncytial virus infection (RSV), sponsored by Ark Biosciences. Started Mar 2019; status: terminated.
02
Drugs
ziresovir
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT03699202.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03699202.